Researchers Identify Unique Immune Cells Possibly Linked to Longevity in Centenarians
A recent study published in Cell Reports has uncovered a potential new mechanism behind the longevity of people aged 100 and above. Researchers found that these centenarians have an increased number of unique immune cells, specifically CD4 cytotoxic T lymphocytes (CTLs), which may protect them from cancer. The study showed that the proportion of these CD4 CTLs rises with age, and intriguingly, none of the centenarians in the study had ever developed cancer, suggesting these cells might play a crucial protective role.
This discovery builds on earlier findings from 2019, where elevated levels of CD4 T cells were observed in individuals aged 110 and older. The current research indicates that some of these immune cells resemble those found in younger cancer patients, known for their ability to combat tumors. While CD4 CTLs have primarily been studied in cancer patients, scientists speculate that in centenarians, these cells might also defend against other threats, potentially contributing to their extended lifespan and health.
The hypothesis that centenarians produce these immune cells more efficiently is still preliminary but opens exciting new avenues for aging research. The study highlights the importance of immune system function in healthy aging and longevity, suggesting future research could explore therapeutic strategies to enhance these protective immune responses.
Separately, the article also mentions recent FDA approval for a new blood test by Eli Lilly and Roche to detect Alzheimer’s disease in individuals over 55 with mild cognitive decline. This test, characterized by low false-negative rates, represents a significant advancement in early diagnosis, potentially improving treatment outcomes. Additionally, the World Health Organization recognized Israeli healthcare organizations for successful AI integration projects, including efforts by Clalit Health Services and Sheba Medical Center to improve disease detection and patient care.
In the financial sector, the Israeli R&D partnership Almada has rebounded after significant losses, driven by a lucrative exit of one of its portfolio companies, BioProtect, sold for $270 million. Almada’s portfolio includes promising medical startups, although some face financial challenges. The article concludes with a note on the development of a new northern district in Ashdod, Israel.
